Ask AI

Applying the Latest Data and Expert Guidance for CSF1R-Targeted Treatment of TGCT

Video
This activity is available for 0.25 CME/CE credit(s).

Released: August 24, 2026

Expiration: February 23, 2027

See Activity Collection

In this video-based module, expert faculty examines evolving treatment strategies for tenosynovial giant cell tumor (TGCT), with emphasis on individualized decision-making for patients with symptomatic, progressive, or function-limiting disease. The activity reviews when observation, surgery, systemic therapy, or combined approaches may be appropriate; the limitations and potential morbidity of surgery, particularly in diffuse-type TGCT; and phase III evidence from the ENLIVEN and MOTION trials investigating CSF1R-targeted therapies. In addition, the faculty discusses emerging agents, treatment duration and sequencing, monitoring for progressive joint damage, and the role of multidisciplinary care and shared decision-making in balancing disease control, treatment burden, toxicity, quality of life, and preservation of joint function.

CSF1R Targeted Tx for TGCT

AI Simulator Patient Course

You have completed this course. Would you like to retake this?

Activity Information

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: August 24, 2026

Expiration: February 23, 2027